Clinical Trial Update: A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

This Phase 3 trial compares JNJ-68284528, a BCMA-directed CAR-T therapy, with pomalidomide-bortezomib-dexamethasone (PVd) or daratumumab-pomalidomide-dexamethas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)
• JNJ-68284528
• Pomalidomide (Pomalidomide)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multiple Myeloma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-05-20